1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Biosimilars Council Commends Nixing ‘Arbitrary’ Interchangeability Designation

The Proposal Was Included In President Biden’s FY2025 Budget Request

 
• By Urtė Fultinavičiūtė

The Biosimilars Council agreed with the US president’s proposal to remove the “unnecessary” designation for biosimilars, which strengthens the ongoing debate over the need for interchangeability.

Person putting files into a bin
• Source: Shutterstock

The Biosimilars Council, a division of US off-patent group the Association for Accessible Medicines, has applauded US president Joe Biden’s latest move to eliminate the biosimilar interchangeability designation in his fiscal year 2025 budget request.

Calling interchangeability an “arbitrary distinction”, the Biosimilars Council said that the US is the “only country in the world with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.